Last Updated : April 18, 2024
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
insulin icodec (Awiqli)
Therapeutic Area: Diabetes mellitus, type 2
Draft recommendations posted for stakeholder feedback: April 18, 2024
End of feedback period: May 03, 2024
Draft Recommendation
bimekizumab (Bimzelx)
Therapeutic Area: Psoriatic arthritis
Draft recommendations posted for stakeholder feedback: April 18, 2024
End of feedback period: May 03, 2024
Draft Recommendation
bimekizumab (Bimzelx)
Therapeutic Area: Ankylosing spondylitis
Draft recommendations posted for stakeholder feedback: April 18, 2024
End of feedback period: May 03, 2024
Draft Recommendation
dostarlimab (Jemperli)
Therapeutic Area: Endometrial cancer
Draft recommendations posted for stakeholder feedback: April 4, 2024
End of feedback period: April 18, 2024
Draft Recommendation
cemiplimab (Libtayo)
Therapeutic Area: Locally advanced or metastatic NSCLC (first line)
Draft recommendations posted for stakeholder feedback: April 4, 2024
End of feedback period: April 18, 2024
Draft Recommendation
Open Calls for Patient and Clinician Input
Therapeutic Area
Therapeutic Area:
Iron deficiency anemia
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Advanced Systemic Mastocytosis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Activated phosphoinositide 3 kinase delta syndrome
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Relapsed or refractory multiple myeloma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
ALK-positive NSCLC
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Gastrointestinal cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Polyneuropathy in hereditary transthyretin-mediated amyloidosis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Pulmonary arterial hypertension (WHO group 1)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Last Updated : April 18, 2024